Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer

No AccessJournal of UrologyAdult Urology1 May 2014Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer Tobias Klatte, Evanguelos Xylinas, Malte Rieken, Luis A. Kluth, Morgan Rouprêt, Armin Pycha, Harun Fajkovic, Christian Seitz, Pierre I. Karakiewicz, Yair Lotan, Marko Babjuk, Michela de Martino, Douglas S. Scherr, and Shahrokh F. Shariat Tobias KlatteTobias Klatte Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria , Evanguelos XylinasEvanguelos Xylinas Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York Department of Urology, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris Descartes University, Paris, France , Malte RiekenMalte Rieken Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York , Luis A. KluthLuis A. Kluth Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany , Morgan RouprêtMorgan Rouprêt Department of Urology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancérologie GRC5, University Paris 6, Paris, France Department of Urology, University Hospital Basel, Basel, Switzerland , Armin PychaArmin Pycha Department of Urology, Central Hospital of Bolzano, Bolzano, Italy , Harun FajkovicHarun Fajkovic Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria , Christian SeitzChristian Seitz Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria , Pierre I. KarakiewiczPierre I. Karakiewicz Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada , Yair LotanYair Lotan Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas , Marko BabjukMarko Babjuk Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic , Michela de MartinoMichela de Martino Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria , Douglas S. ScherrDouglas S. Scherr Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York , and Shahrokh F. ShariatShahrokh F. Shariat Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York View All Author Informationhttps://doi.org/10.1016/j.juro.2013.11.106AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. Materials and Methods: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. Results: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type. Conclusions: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated. References 1 : Cancer statistics, 2013. CA Cancer J Clin2013; 63: 11. Google Scholar 2 : EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol2013; 64: 639. Google Scholar 3 Clark PE, Agarwal N, Biagioli MC et al: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 1.2013. Available at http://nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed September 15, 2013. Google Scholar 4 : Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol2009; 182: 2195. Link, Google Scholar 5 : Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006; 49: 466. Google Scholar 6 : The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol2011; 60: 423. Google Scholar 7 : Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. Urology2013; 82: 387. Google Scholar 8 : Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene2006; 25: 2685. Google Scholar 9 : Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer2005; 104: 1918. Google Scholar 10 : The blood group ABO gene transcript is down-regulated in human bladder tumors and growth-stimulated urothelial cell lines. Cancer Res1996; 56: 1031. Google Scholar 11 : Influence of blood group type on the natural history of superficial bladder cancer. J Urol1987; 138: 758. Abstract, Google Scholar 12 : ABO blood groups and bladder carcinoma. Eur Urol1990; 17: 289. Google Scholar 13 : Relationship of blood groups and bladder cancer. J Urol1986; 135: 50. Link, Google Scholar 14 : Relationship between blood groups and tumour grade, number, size, stage, recurrence and survival in patients with transitional cell carcinoma of the bladder. Scand J Urol Nephrol1993; 27: 343. Google Scholar 15 : Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology2009; 20: 555. Google Scholar 16 : A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet2008; 4: e1000072. Google Scholar 17 : Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta1999; 1473: 247. Google Scholar 18 : Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. Int J Cancer1998; 75: 819. Google Scholar 19 : Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest2005; 85: 895. Google Scholar 20 : What a difference 2 nucleotides make: a short review of ABO genetics. Transfus Med Rev2005; 19: 200. Google Scholar 21 : Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer2004; 109: 230. Google Scholar 22 : Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A2002; 99: 10231. Google Scholar 23 : Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. Cancer Res1997; 57: 3092. Google Scholar 24 : Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J Urol1980; 124: 27. Abstract, Google Scholar 25 : The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol1999; 162: 74. Link, Google Scholar 26 : Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer?. Pro. J Urol2011; 186: 787. Abstract, Google Scholar © 2014 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 191Issue 5May 2014Page: 1238-1243Supplementary Materials Advertisement Copyright & Permissions© 2014 by American Urological Association Education and Research, Inc.Keywordsurinary bladderABO blood-group systemneoplasm recurrencelocaldisease progressioncarcinomaMetricsAuthor Information Tobias Klatte Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria More articles by this author Evanguelos Xylinas Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York Department of Urology, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris Descartes University, Paris, France More articles by this author Malte Rieken Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York More articles by this author Luis A. Kluth Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany More articles by this author Morgan Rouprêt Department of Urology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancérologie GRC5, University Paris 6, Paris, France Department of Urology, University Hospital Basel, Basel, Switzerland More articles by this author Armin Pycha Department of Urology, Central Hospital of Bolzano, Bolzano, Italy More articles by this author Harun Fajkovic Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria More articles by this author Christian Seitz Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria More articles by this author Pierre I. Karakiewicz Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada More articles by this author Yair Lotan Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Marko Babjuk Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic More articles by this author Michela de Martino Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria More articles by this author Douglas S. Scherr Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York More articles by this author Shahrokh F. Shariat Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York More articles by this author Expand All Advertisement PDF DownloadLoading ...